ASH 2014: Phase I study shows that daratumumab combined with standard myeloma therapy improves outcomes in relapsed and refractory myeloma

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr María-Victoria Mateos (Hospital Universitario de Salamanca, Salamanca, Spain) discusses the open-label, multicentre, phase 1b study of daratumumab in combination with standard regimens in patients with multiple myeloma. Standard regimens included bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.